106Ru radiolabelling of the antitumour complex [(η6-fluorene)Ru(en)Cl]PF6

被引：17

作者：

Hoeschele, James D. ^{[1
]}

Habtemariam, Abraha

Muir, Jeanette

Sadler, Peter J.

机构：

[1] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA

[2] Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland

来源：

DALTON TRANSACTIONS | 2007年 / 43期

关键词：

D O I：

10.1039/b706246j

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The organometallic half-sandwich Ru-II arene anticancer complex [( eta(6)-fluorene) Ru( en) Cl] PF6 ( 1) has been synthesized in high yield and purity on a micromole scale with incorporation of the beta-emitting radioisotope Ru-106 ( half-life = 1.01 y) using a refined procedure involving conversion of RuCl3 into [( eta(6)-fluorene)RuCl2](2), and then [(eta(6)-fluorene)Ru(CH3CN)(2)Cl]PF6 as intermediates. Distribution studies 0.25 h post i.v. injection of Ru-106-1 at a dose of 25 mg 1 kg(-1) show that Ru-106 is well distributed throughout the tissues of a rat. This appears to be the first report of the radiolabelling of a potential ruthenium antitumour agent for distribution/biological studies.

引用

页码：4974 / 4979

页数：6

共 11 条

[1] In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].

Aird, RE ;

Cummings, J ;

Ritchie, AA ;

Muir, M ;

Morris, RE ;

Chen, H ;

Sadler, PJ ;

Jodrell, DI .

BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657

[2]

Alessio E, 2004, MET IONS BIOL SYST, V42, P323

[3] Ruthenium metallopharmaceuticals (vol 232, pg 69, 2002) [J].

Clarke, MJ .

COORDINATION CHEMISTRY REVIEWS, 2003, 236 (1-2) :207-+

[4] Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds [J].

Guichard, SM ;

Else, R ;

Reid, E ;

Zeitlin, B ;

Aird, R ;

Muir, M ;

Dodds, M ;

Fiebig, H ;

Sadler, PJ ;

Jodrell, DI .

BIOCHEMICAL PHARMACOLOGY, 2006, 71 (04) :408-415

[5] Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands [J].

Habtemariam, Abraha ;

Melchart, Michael ;

Fernandez, Rafael ;

Parsons, Simon ;

Oswald, Iain D. H. ;

Parkin, Andrew ;

Fabbiani, Francesca P. A. ;

Davidson, James E. ;

Dawson, Alice ;

Aird, Rhona E. ;

Jodrell, Duncan I. ;

Sadler, Peter J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) :6858-6868

[6]

Hamaoka T., 1990, CELL TECHNOLOGY, V9, P456

[7] From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) [J].

Hartinger, Christian G. ;

Zorbas-Seifried, Stefanie ;

Jakupec, Michael A. ;

Kynast, Bernd ;

Zorbas, Haralabos ;

Keppler, Bernhard K. .

JOURNAL OF INORGANIC BIOCHEMISTRY, 2006, 100 (5-6) :891-904

[8]

MORI K, 1994, PROTEIN NUCLEIC ACID, V39, P181

[9] Inhibition of cancer cell growth by ruthenium(II) arene complexes [J].

Morris, RE ;

Aird, RE ;

Murdoch, PD ;

Chen, HM ;

Cummings, J ;

Hughes, ND ;

Parsons, S ;

Parkin, A ;

Boyd, G ;

Jodrell, DI ;

Sadler, PJ .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (22) :3616-3621

[10] SILICON-MODIFIED METAL-AMMONIA REDUCTION OF FLUORENE [J].

SMITH, WK ;

HARDIN, JN ;

RABIDEAU, PW .

JOURNAL OF ORGANIC CHEMISTRY, 1990, 55 (18) :5301-5302

← 1 2 →